摘要
目的:观察清肺方联合奥司他韦胶囊治疗热毒袭肺型流行性感冒(以下简称“流感”)低热患者的疗效及安全性。方法:选取2022年1—12月就诊于样本医院的60例流感患者作为研究对象,采用随机数表法将其分为观察组与对照组,每组各30例。对照组患者应用奥司他韦胶囊,观察组患者应用清肺方联合奥司他韦胶囊。两组患者均服药5 d。比较两组患者治疗前后血清指标[白细胞(WBC)、C反应蛋白(CRP)、淋巴细胞计数(LYM)]、体温、发热持续时间、症状积分、中医证候积分、不良反应、安全性指标[血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、尿素氮(BUN)、肌酐(Cr)、总胆红素(TBIL)]情况。结果:治疗后,观察组患者WBC、LYM、CRP水平均明显低于对照组,差异均有统计学意义(t=-5.23、-6.82、-4.18,P<0.001)。治疗后,观察组患者体温低于对照组,差异有统计学意义(t=-1.23,P<0.05)。观察组患者发热持续时间短于对照组,差异有统计学意义(t=-5.02,P<0.001)。治疗后,观察组患者症状积分、中医证候积分明显低于对照组,差异均有统计学意义(t=-7.08、-5.10,P<0.001)。两组患者均未出现不良反应。结论:清肺方联合奥司他韦胶囊能明显缩短流感发热持续时间,改善患者症状,降低炎症反应水平,未发生不良反应。
Objective:To observe the effect of Qingfei prescription and Oseltamivir Capsuon on patients with low influenza fever(heat toxin attacking lung type).Methods:60 influenza patients treated in the hospital from January to December 2022 were selected as the subjects.They were divided into control group and observation group by random number table,with 30 patients in each group.The control group took Oseltamivir Phosphate Capsules orally,and the observation group took Qingfei Prescription in combination with Oseltamivir Phosphate Capsules,with a course of treatment lasting for 5 days.The serum indicators[white blood cell(WBC),C-reactive protein(CRP),lymphocyte count(LYM)],body temperature,duration of fever,symptom score,TCM syndrome score,adverse reactions,and safety indicators[serum alanine aminotransferase(ALT),aspartate aminotransferase(AST),blood urea nitrogen(BUN),creatinine(Cr)and total bilirubin(TBIL)]before and after treatment were compared between the two groups.Results:After treatment,the levels of WBC,LYM and CRP in the observation group were significantly lower than those in the control group,and the differences were statistically significant(t=-5.23,-6.82,-4.18;P<0.001).After the treatment,the body temperature of patients in the observation group was lower than that in the control group,and the difference was statistically significant(t=-1.23,P<0.05).The duration of fever in the observation group was shorter than that in the control group,and the difference was statistically significant(t=-5.02,P<0.001).After the treatment,the symptom scores and TCM syndrome scores of the patients in the observation group were significantly lower than those in the control group,and the differences were statistically significant(t=-7.08,-5.10;P<0.001).No adverse reactions occurred in either group.Conclusion:Qingfei Prescription combined with Oseltamivir Phosphate Capsules have significantly shortened the duration of fever in influenza patients,improved their symptoms,and reduced the level of inflammatory response,with no adverse reactions.
作者
郭玉飞
刘攀
徐航
Guo Yufei;Liu Pan;Xu Hang(Emergency Department,Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital Anhui Branch,Hefei,Anhui,230031,China)
出处
《黑龙江医学》
2025年第16期1986-1989,共4页
Heilongjiang Medical Journal
基金
安徽中医药大学科研基金项目(2021sfylc18)。
关键词
流感
发热
清肺方
随机对照试验
Influenza
Fever
Qingfei prescription
Randomized controlled trial
